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Abstract
Conjugated linoleic acid (CLA) has been the subject of extensive investigation regarding its possible
benefits on a variety of human diseases. In some animal studies, CLA has been shown to have a
beneficial effect on sclerotic lesions associated with atherosclerosis, be a possible anti-carcinogen,
increase feed efficiency, and act as a lean body mass supplement. However, the results have been
inconsistent, and the effects of CLA on atherogenesis appear to be dose-, isomer-, tissue-, and
species-specific. Similarly, CLA trials in humans have resulted in conflicting findings. Both the human
and animal study results may be attributed to contrasting doses of CLA, isomers, the coexistence
of other dietary fatty acids, length of study, and inter-and/or intra-species diversities. Recent
research advances have suggested the importance of CLA isomers in modulating gene expression
involved in oxidative damage, fatty acid metabolism, immune/inflammatory responses, and
ultimately atherosclerosis. Although the possible mechanisms of action of CLA have been
suggested, they have yet to be determined.
Conjugated linoleic acid
A group of trans-fatty acids, conjugated linoleic acid (CLA)
has been purported to have diverse physiological func-
tions and potential health benefits [1-6]. These unique
geometric and positional isomers of octadecadienoic acid
derived from linoleic acid (18:2n-6) have been found in
only a limited number of foods or food products mostly
derived from the fat of range animals. The highest levels
of CLA are found in ruminant animals (beef, lamb and
dairy cows) with beef, milk-fat, and cheese, the most com-
mon animal products containing CLA. During the biohy-
drogenation of linoleic acid to stearic acid, CLA is
synthesized in the rumen as an intermediate by gram-neg-
ative bacteria, Butyrivibrio fibrisolvens [7]. CLA is also
found in fish, monogastric animal products, and plant
products, however, in much lower concentrations [3].
CLA isomers have been identified during the hydrogena-
tion of fat, e.g., margarine production, and are found pri-
marily in foods considered high in fat. Also, CLA is found
in low concentrations in the lipids of human blood, tis-
sue, and milk [8], presumably from dietary intakes.
Although there are 28 different CLA isomers, the cis-9,
trans-11 CLA isomer is predominantly found in the rumi-
nant foods discussed earlier and accounts for >90% of
CLA intake in the human diet [9]. The structures, shown
in Figure 1, consist of 18 carbon atoms with two conju-
gated double bonds separated by a single bond, unlike
linoleic acid, which is a non-conjugated diene [1]. The
conjugated double bonds of CLA isomers contribute to
their higher susceptibility to autioxidation than the non-
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conjugated bonds of linoleic acid [10]. Differences in
chain length, degree of unsaturation, and position and
stereoisomeric configuration of the double bonds affect
fatty acid oxidation or lipid peroxidation. Usually, long-
chain fatty acids are oxidized more slowly and unsatu-
rated fatty acids are oxidized more rapidly than are satu-
rated fatty acids. Lauric acid is highly oxidized, but PUFAs
and monounsaturated fatty acids are fairly well oxidized
[11]. Oxidation of the long-chain, saturated fatty acids
decreases with increasing carbon number.
Many research groups have looked at the possibility of
CLA isomers as anti-carcinogens. Most anti-carcinogens
are plant products (phytochemical), therefore, CLA iso-
mers are unusual find because it occurs in the highest con-
centration in animal products (zoochemical) with only
trace amounts found in plant lipids. The possibility of
CLA isomers working as a feed efficiency supplement and
a lean body mass supplement has also been examined,
along with its role in cancer prevention and stimulation of
the immune system.
With regard to potential health benefits, considerable
attention has been given to anti-carcinogenic effects of
CLA isomers; however, less attentions has been devoted
toward its usefulness in preventing and reversing athero-
sclerosis and related diseases. The majority of research
studies have been done using experimental animals and in
vitro, with only recent investigations showing the effects of
CLA isomers on humans. The purpose of this review is to
assess and summarize current literature and knowledge
on the possible health benefits of CLA isomers, particu-
larly with respect to atherosclerosis as a chronic inflam-
matory disease.
Pathology/etiology of atherosclerosis
Cardiovascular disease (CVD) is a major cause of death in
developed countries, and most cardiovascular events are
secondary to atherosclerosis [12]. CVD causes high medi-
cal costs and losses of productivity. The high incidence of
CVD mortality and morbidity and the economic toll of
CVD emphasize the need for prevention and management
of CVD associated risk factors. Although the risks for CVD
are multifactorial, the three most important modifiable
risk factors for atherosclerosis are: 1) smoking, 2) inactive
lifestyle, and 3) elevated blood cholesterol levels from
dietary sources. Of particular concern for the elevated
blood cholesterol is increased low-density lipoprotein
(LDL). Results of extensive epidemiological and clinical
research support the direct association between elevated
blood cholesterol and CVD risk.
Atherosclerosis is a condition characterized by degenera-
tion and hardening of the walls of the arteries and some-
times the valves of the heart. There is accumulation of
lipids and other materials in the arteries which contrib-
utes to hypertension and vice versa. Figure 2 schematically
illustrates the major points of oxidized LDL in the process
of plaque formation. The process of atherosclerosis begins
with buildup of soft fatty streaks along the inner arterial
walls often at branch points. With age, fatty streaks stead-
ily grow and become hardened with minerals, leading to
plaque. Consequently, plaque stiffens and narrows the
artery lumen. By middle age, most people have well-rec-
ognized plaque formation [13]. Blood platelets respond
to plaque as if it was a blood vessel injury produce clots
which unlike the normal blood clotting events, do not
readily dissolve and instead stick to the plaque, grow and
restrict blood flow, i.e., thrombosis. Platelet activity is
under the control of eicosanoids synthesized from 20-car-
bon omega-6 and omega-3 fatty acids, such as prostaglan-
dins and thromboxanes. Complication may occur when
blood clots break free from the walls of arteries and make
their way to a smaller artery, and shut off the blood supply
to tissue; this produces an embolism.
Chemical structures of linoleic acid and isomers of conju- gated acid (CLA) Figure 1
Chemical structures of linoleic acid and isomers of 
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LDL oxidation is thought to be the first step of atherogen-
esis, followed by foam cell, fatty streak, and plaque forma-
tion. It has been hypothesized that LDL can be
transported through endothelial tight junctions and/or
endothelial transcytosis from the lumen into the intima
[14], in which blood antioxidants are unlikely to be avail-
able, and undergo atherogenic oxidative changes. Modi-
fied LDL is then taken up by macrophages through
multiple pathways. Minimally oxidized LDL (MM-LDL) is
recognized by CD14 and toll-like receptor-4 (TLR4) [15],
while oxidized LDL binds to scavenger receptors (e.g.,
CD36, CD68, SR-A1, SR-B1). Aggregated forms of either
MM-LDL or native LDL are endocytosed by activated mac-
rophages [16].
Both oxidized LDL and activated macrophages by oxi-
dized LDL uptake affect gene expression in neighboring
endothelial cells (ECs), contributing to further athero-
genic/inflammatory processes. Studies have documented
that the oxidized LDL affect the pattern of gene expression
in ECs, leading to up-regulated expression of target mole-
cules. The oxidized LDL-induced molecules in ECs
include monocyte chemoattractant proteins (MCPs),
macrophage colony stimulating factors (M-CSFs), and cell
adhesion molecules (CAMs) [17,18]. MCPs and M-CSFs
are induced by MM-LDL, and are released from ECs. MCPs
recruit monocytes to the ECs. M-CSFs promote the differ-
entiation and proliferation of monocytes to macrophages
(Figure 2). CAMs, cell surface proteins, are involved in
binding with other cells or the extracellular matrix. These
molecules contribute to foam cell formation by the
recruitment of circulatory monocytes into vascular walls
and by the stimulation of monocyte differentiation to
macrophages.
The differences in genetic susceptibility to atherosclerosis
were investigated using animal and human models [19-
22]. ECs from the atherosclerotic prone strain of C57BL/
6J mice exhibited dramatic induction of MCP-1 and M-
CSF in response to MM-LDL, while ECs from the athero-
sclerotic resistant strain of C3H/HeJ mice showed little or
no induction of MCP-1 or M-CSF. Shi et al. [19] provide
the evidence that genetic factors influencing the endothe-
lial response to oxidized LDL contribute to the genetic
component in atherosclerosis. Levula et al.'s [20] microar-
ray study reveals the groups of target genes whose expres-
sions are altered by oxidized LDL in human macrophages.
The target genes are involved in 1) lipid metabolism, 2)
inflammation, growth, and hemostasis, 3) metalloprotei-
nases and tissue inhibitors of matrix metalloproteinases,
4) enzymes, 5) structural and binding proteins, and 6)
annexins. The genes involved in inflammation include M-
CSF1, MCP1, and ICAM1, all of which are induced in the
macrophages by oxidized LDL, and correspond to the
results of previous Shi et al.'s EC studies.
Induced expression of CD68 and SR in human macro-
phages by oxidized LDL was also observed in Levula et al.'s
microarray study. In addition, activated macrophages
secrete inflammatory cytokines, such as TNF-α, that con-
tribute to the induction of the expression of MCP-1, M-
CSF, ICAM1, and VCAM1 in human aortic endothelial
cells (HAECs) [21] and the expression of ICAM1 and
VCAM1 in human neonatal dermal lymphatic endothelial
cells (HNDLECs) [22] and the development of atheroscle-
Vascular events leading to the development of atherosclerotic lesions Figure 2
Vascular events leading to the development of atherosclerotic lesions. Low density lipoprotein (LDL), scavenger 
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rosis. Thus, the pro-inflammatory gene expression in ECs
is mediated by either oxidized LDL or pro-inflammatory
cytokines released from activated macrophages, resulting
in augmented atherogenic/inflammatory events by
recruiting circulatory monocytes.
Moreover, oxidized LDL may modulate the apoptosis of
vascular cells. Reeve et al's [23] microarray study demon-
strated that 221 genes were differentially regulated by oxi-
dized LDL in coronary artery smooth muscle cells
(CASMC). Of particular interest are apoptotic genes, FasL,
Bax, and p53, induced by oxidized LDL in CASMC. Oxi-
dized LDL induces apoptosis of ECs via the mitogen-acti-
vated protein kinase (MAPK) pathway [24]. Studies using
EC and smooth muscle cell cultures demonstrated that
multiple apoptotic signaling pathways were affected by
ROS [25].
Roles of ROS in atherogenesis
Reactive oxygen species (ROS) are implicated in athero-
genesis. Risk factors for atherosclerosis are associated with
an increased arterial wall flux of ROS that not only may
oxidize biomolecules, but also directly produce pheno-
typic changes in vascular cells, including the induction of
adhesion molecules and smooth muscle proliferation
[26].
Sources of ROS
Sources of ROS involved in atherogenesis include NADPH
oxidases, nitric oxide synthases (NOS), lipoxygenases
(LO), cyclooxygenases (COX), and the mitochondrial res-
piratory chain [27]. Native LDL is modified by ROS gen-
erated by these enzymes in vascular tissues. NADPH
oxidase is composed of a number of different subunits.
There are seven homologues of the gp91phox (Nox-2)
subunit. Nox-4 is predominantly expressed in ECs,
though the expressions of Nox-1 and Nox-2 are also
detected [28]. During the respiratory burst in phagocytes,
NADPH oxidase converts oxygen molecules to superox-
ide, which is a microbicidal oxygen metabolite. Then,
superoxide is converted by superoxide dismutase (SOD)
to hydrogen peroxide, which also kills microorganisms.
ROS are also produced in ECs by endothelial NADPH oxi-
dase [26,27]. Phagocytic NADPH oxidase and endothelial
NADPH oxidase is one of the major ROS sources in the
vasculature [27]. Monocyte differentiation to macrophage
is associated with the production and the release of ROS
possibly through the induction of NADPH oxidase, result-
ing in further LDL oxidation [29,30]. NADPH oxidase
generates superoxide on the extracellular side of the
plasma membrane, and the enzyme can trigger intracellu-
lar signaling by superoxide transport via chloride channel-
3 [31]. Stepp et al. [32] reported that native LDL and MM-
LDL differentially increase vascular endothelial superox-
ide generation in canine carotid arteries, leading to vascu-
lar dysfunction and atherogenesis. Native LDL increases
superoxide by an endothelial nitric oxide synthase
(eNOS)-dependent mechanism whereas MM-LDL
induces greater superoxide by the mechanisms dependent
on eNOS, xanthine oxidase, and NADPH oxidase. Super-
oxide production by vascular tissues and its interaction
with nitric oxide (NO) play important roles in vascular
pathophysiology. Superoxide reacts rapidly with NO,
reducing NO bioavailability and producing the oxidative
peroxynitrite radical [33]. Endothelial activation via LOX-
1 produces additional ROS, generating a positive feedback
loop for further LDL oxidation [34]. ROS generated in a
NADPH oxidase-dependent pathway mediate TNF-α-
induced MCP-1 expression in ECs, and the induction of
MCP-1 expression is suppressed by the antioxidant
enzymes, SOD and catalase [35]. Since phagocytic
NADPH oxidase is the first line of the host defense system,
selective suppression of vascular NADPH oxidase in local
inflammatory lesions might be one of the therapeutic
strategies [36].
Cyclooxygenases (COX-1 or COX-2) and lipoxygenases
(5-, 12-, or 15-LO) also contribute to ROS generation dur-
ing arachidonic acid (AA) metabolism shown in Figure
3[27,37]. The initial products in AA metabolism are
highly reactive peroxides. Overexpression or induction of
COX-2 increases ROS in certain cell types [38,39] and the
effects of overexpression of COX-2 are cell-/tissue-specific
[40]. Constitutive COX-1 and inducible COX-2 catalyze
the conversion of free PUFAs to prostanoids (prostaglan-
dins and thromboxanes), while LO generates the leukot-
rienes. Prostanoids and leukotrienes comprise a large and
complex family of biologically active lipids derived from
PUFAs by insertion of molecular oxygen. Collectively,
these compounds are termed eicosanoids. Both prosta-
noids and leukotrienes play important roles in inflamma-
tion. Non-esterified PUFA released from the sn-2 position
(middle carbon of glycerol) of the membrane phospholi-
pids by the action of specific phospholipases are sub-
strates for COX, LO, or cytochrome P450
monooxygenases (CYP) [41,42]. The metabolism of AA
has two main pathways: the cyclic pathway leading to
prostanoid formation and the linear pathway resulting in
leukotriene formation. Two molecules of oxygen are
added in the first step for the generation of prostaglandin
G (PGG). The second step, via the peroxidase activity of
COX, converts PGG2 into PGH2, the precursor for either
thromboxanes or other prostaglandins. The peroxidase
step is inhibited by aspirin or ibuprofen. LO is also a
major source of extracellular superoxide release in a cer-
tain cell type during AA metabolism [37]. The LO pathway
is responsible for the formation of leukotrienes and
hydroxyeicosatetraenoic acids (HETEs). LO isoforms act
upon arachidonic acid to form 5-, 8-,12-, or 15-hydroper-
oxy eicosatetraenoic acids (HPETEs), which are unstableNutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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and can be reduced to the hydroxyl derivatives (HETE) in
vivo. The range of HPETEs with biological activity is
known as the leukotrienes. Both COX and LO products
diffuse from cells and act locally at nanomolar levels on
cell surface receptors linked to G-proteins. Activation of
G-protein-associated receptors leads to changes in intrac-
ellular cAMP or calcium, which serve as second messen-
gers that activate signaling mechanisms influencing
various cellular functions. The COX products are modula-
tors of thromboregulatory and chemotaxic responses, and
inflammation. The LO products are involved in vascular
permeability, vasoconstriction, and bronchoconstriction.
The third route for eicosanoid production is via the CYP,
in particular CYP4 family [43], including epoxy deriva-
tives of 20:4 ω-6 that can modulate calcium signaling,
channel activity, transporter function, and mitosis. This
mechanism seems to be more consequential in cells when
COX and LO activities are minimal.
This body of research has verified that multiple enzymes
are involved in ROS generation that leads to atherogene-
sis. Hence, it is speculated that suppressing ROS genera-
tion may be a therapeutic target for preventing and
alleviating atherosclerosis.
Metabolic pathways for the formation of prostaglandins, thromboxanes, and leukotrienes Figure 3
Metabolic pathways for the formation of prostaglandins, thromboxanes, and leukotrienes. Prostaglandin H2 
(COX), lipoxygenase (LOX), 12-hydroperoxyeicosatetraenoate (12-HPETE), 5-hydroperoxyeicosatetraenoate (5-HPETE).Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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Oxidation of biomolecules
ROS play a role in LDL oxidation. LDLs are rich in poly-
unsaturated fatty acids (PUFAs), which are susceptible to
oxidation [12]. Lipid peroxidation can commence by ROS
and other mechanisms that result in abstraction of an
electron from a PUFA [44]. The sequential carbon-cen-
tered radical undergoes rearrangement, and in the pres-
ence of oxygen, will add oxygen to form a peroxyl radical
(ROO•). Propagation of the free radical reaction can
occur by reaction of the peroxyl radical with another
PUFA, generating the corresponding fatty acid hydroper-
oxide (ROOH) and another carbon-centered radical.
Other factors, such as Fe+2, and other oxidants can result
in an amplification of the free radical process. Vitamin E
is a nonenzymatic chain-breaking scavenger of lipid radi-
cals generated in cell membranes; it protects against fur-
ther lipid peroxidation. Vitamin C is an important
antioxidant against lipid peroxidation because it has a
high reactivity with the oxygen-centered radical. Oxygen-
centered radicals have sufficient polarity to be accessible
to the aqueous soluble vitamin C. Also, when vitamin E
reacts with a radical, vitamin E is converted to its radical
form which can be recycled to reduced vitamin E by react-
ing with vitamin C. Other reducing compounds such as
glutathione and NADPH act in concert with vitamins E
and C in an antioxidant cascade.
LDL oxidation also results in changes in apolipoprotein B
epitope. The oxidized apolipoprotein portion of LDL is
subsequently recognized and internalized by SR-A,
whereas the oxidized lipid moiety of LDL is bound to
CD36 on macrophages [45].
Inflammation and fatty acids/other protective 
compounds
Fatty acids
The relationship between fatty acids and atherosclerosis
and other inflammatory diseases has been suggested by
epidemiological, clinical, and in-/ex-vivo studies.
Increased intake of saturated fatty acids is positively asso-
ciated with development of atherosclerosis and inflam-
mation. In contrast, omega-3 (ω-3) fatty acids, such as
eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic
acid (DHA, C22:6), have shown protective effects against
CVD. EPA and DHA are major components of dietary fish
and fish oils. Like EPA and DHA, CLA isomers, exhibit
protective effects against atherogenesis [46,47] and
inflammatory bowel disease (IBD) [5,48,49] and antioxi-
dant effects [50] in in-/ex-vivo studies; however, clinical
studies have been inconclusive.
Most of the fatty acids synthesized or ingested have one of
two fates: incorporation into triglycerides for the storage
of metabolic energy or incorporation into the phospholi-
pid components of membranes. The selection between
the alternative fates depends on the need (i.e. growth and
starvation) [42]. Fatty acids may differentially affect
inflammatory processes and ultimately the etiology of
atherosclerosis in three ways as:
1) the components of membrane; fatty acids may serve as
precursors of pro- or anti- inflammatory eicosanoids;
2) the components of LDL; fatty acids may differentially
modulate recognition of macrophage receptors and sub-
sequent inflammatory processes and atherogenesis; and
3) the regulators of gene expression; fatty acids may differ-
entially regulate inflammatory gene expression, serving as
ligands for transcription factors (e.g. PPARs).
Almost all mammalian cells, except red blood cells, pro-
duce eicosanoids, which play a role in inflammation. Ara-
chidonic acid (AA, C22:4) is the most important precursor
of eicosanoid, and AA is synthesized from linoleic acid
(LA, C18:2, ω-6) by enlongation and desaturation. In
response to hormonal or other stimuli, phospholipase A2,
present in most types of mammalian cells, attacks mem-
brane phospholipids, releasing AA from the middle car-
bon of glycerol. Enzymes of the smooth endoplasmic
reticulum then convert AA into eicosanoids, potent bio-
logical signaling molecules [42].
LA (18:2, ω-6) and α-linolenic acid (ALA, 18:3, ω-3) serve
as the precursors for longer-chain ω-6 (e.g., arachidonic
acid: AA) and ω-3 fatty acids (e.g., EPA, DHA), respec-
tively. Neither ω-3 nor ω-6 fatty acids can be synthesized
in mammals due to the lack of certain types of desatu-
rases. ω-3 Fatty acids cannot be generated from ω-6 fatty
acids in mammals. Hence, the source of these PUFAs is
limited to dietary intake [51]. Dietary EPA, DHA, and CLA
can partially replace AA derived from LA in the cell mem-
brane [52,53]. Usually the plentiful LA may exclude these
fatty acids from incorporation into membrane phosphol-
ipids [54] and/or LDL. However, EPA, DHA and CLA may
influence eicosanoid production from AA and subsequent
immune and inflammatory processes. For example EPA
and DHA decrease the synthesis of pro-inflammatory
eicosanoids, such as leukotriene-4 and prostaglandin-2 by
replacing AA in phospholipid bilayers and by inhibiting
cycloxygenase activity [55-57]. As components of LDL
and/or membrane, these fatty acids may affect the inflam-
matory gene expression by altering signaling pathways.
The unusual conformation structures (kinks) in unsatu-
rated fatty acids interfere with the membrane motion [42]
and possibly signal transduction. In addition, EPA and
DHA reduce the expression of adhesion molecules
induced by oxidized LDL in endothelial cells [58-60]. ω-3
PUFAs suppress inflammatory gene expression by inhibit-
ing TLR4 signaling pathway, whereas saturated fatty acidsNutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
Page 7 of 20
(page number not for citation purposes)
exhibit the opposite effect [61], Thus, subsequently
decreasing risk for CVDs.
Phytochemicals/dietary antioxidants
Several epidemiological studies have reported an inverse
relationship between intake of vegetables and fruits (in
particular those rich in antioxidant vitamins including
vitamins C and E and β-carotene), and risk for CVD [62-
65]. The protective effects of these antioxidant vitamins
on atherosclerosis have been intensively investigated in
animal and human studies. According to the oxidative
modification hypothesis, oxidized LDL is immunogenic
and atherogenic and LDL oxidation triggers atheroscle-
rotic processes. Therefore, the protection of LDL from oxi-
dation may be crucial to the prevention of atherosclerosis;
the antioxidant components of LDL may prevent LDL oxi-
dation.
Vitamin E is the generic term for all tocopherol and tocot-
rienol derivatives that exhibit the biological activity of α-
tocopherol. There are eight naturally occurring isoforms
synthesized in plants. α-Tocopherol is the most biologi-
cally and chemically active form of vitamin E. The
hydroxyl groups at the C-6 position of tocopherols enable
them to scavenge free radicals and superoxide. Although
γ-tocopherol is predominant in the American diet, its
plasma levels are only 10% of plasma α-tocopehrol levels
(about 25 μmol/L α-tocopherol) [66].
α-Tocopherol is the major antioxidant in LDL and one
LDL particle contains approximately six molecules of α-
tocopherol. α-Tocopherol in LDL plays a role in prevent-
ing LDL oxidation. Vitamin E depletion in LDL may trig-
ger LDL oxidation; and the addition of micromolar
concentrations of vitamin E inhibits LDL oxidation. All
other antioxidants, such as γ-tocopherol, carotinoids, and
ubiquinol-10, are present in much smaller amounts than
α-tocopherol. In contrast to α-tocopherol, carotenoids
play only a minor or no role in LDL protection [67]. How-
ever, many clinical studies have failed to demonstrate the
protective effects of vitamin E. One explanation may be
that vitamin E exhibits prooxidant activity in the absence
of co-antioxidant compounds capable of reducing the
tocopherol radical [68,69]. A similar situation may occur
with other antioxidants, such as β-carotene [70-72].
Depending on the concentrations, environmental condi-
tions and presence of oxygen or other oxidants, com-
pounds with antioxidant properties may exhibit
prooxidant or other non-antioxidant properties.
Polyphenolic compounds, such as resveratrol and cate-
chins, are derived from plants, and the compounds have
shown anti-atherogenic and anti-inflammatory effects.
The beneficial effects of the compounds are attributed to
their abilities to function as antioxidants by: 1) inhibition
of prooxidant enzymes, such as lipoxygenases, cyclooxy-
genases, and xanthine oxidase, possibly through suppress-
ing the activation of redox-sensitive transcription factors,
NF-κB and activator protein-1 (AP-1), and 2) induction of
antioxidant enzymes such as glutathione S-transferase,
glutathione peroxidase (Gpx), superoxide dismutase
(SOD), and catalase [73,74].
Endogenous/enzymatic antioxidants
Antioxidant enzymes are involved in the maintenance of
intracellular and extracellular reducing reactions [75] and
suppress the generation of free radicals as the first line of
antioxidant defense [12]. Antioxidant enzymes include
superoxide dismutase (SOD) and catalase. SOD is
expressed in most cell types, and converts harmful super-
oxide to less harmful hydrogen peroxide and oxygen. Cat-
alase catalyzes the dismutation of hydrogen peroxide to
oxygen and water. Catalase has an iron redox center. Cat-
alase is located predominantly within peroxisomes to pro-
tect from hydrogen peroxide generated during fatty acid β-
oxidation within the cellular organelles [76].
The antioxidant enzymes play a role in preventing athero-
genesis. Increased expression of GR in macrophages
reduces atherosclerotic lesion formation in LDL receptor-
deficient mice [77]. Over-expression and/or induction of
CuZn-SOD and catalase can be beneficial because of: 1)
decreases in superoxide levels in ECs; 2) suppression of
oxidative stress, e.g., age related; 3) protection against
inflammatory events by inhibiting NF-κB activation; and
4) suppression of low-density lipoprotein (LDL) oxida-
tion by ECs [50,76,78-81].
Target genes/signaling pathway
Atherosclerosis is a chronic inflammatory disease with an
underlying abnormality in redox-mediated signals in the
vasculature [82]. ROS play a role in the signaling involved
in atherogenic/inflammatory processes. There are two
major redox-sensitive signaling pathways related to the
atherogenic/inflammatory processes: NF-κB-, and peroxi-
some proliferator-activated receptor (PPAR)-mediated
pathways. Fatty acids may act as gene regulators. CLA iso-
mers are ligands with high to moderate affinity and acti-
vators of PPAR α and γ. CLA isomers may induce
responsive genes of both PPAR α and γ in vivo [6]. The
trans-10, cis-12 CLA isomer inhibits the NF-κB p50 and
p65 subunits binding to DNA [83]. Also, CLA isomers
may involve the control of redox status by regulating
genes, whose products influence ROS generation, through
transcription factors (PPARγ and NF-κB), which are con-
centration-dependent [84].
NF-κB
NF-κB is a redox-sensitive transcription factor expressed in
all cell types; it recognizes and binds to specific DNANutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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sequences (5'-GGGRNNYYCC-3'). NF-κB activation is
triggered by the IκB kinase (IKK)-mediated degradation of
inhibitor κB (IκB), which regulates NF-κB. NF-κB is acti-
vated by intra-/extra-cellular ROS and/or ROS-modified
target biomolecules, and is involved in regulating
immune and inflammatory responses. NF-κB-mediated
target genes include: inflammatory cytokines (e.g., TNF-a,
IL-1, IL-2, M-CSF), chemokines (e.g., MCP-1), adhesion
molecules (e.g., ICAM-1, VCAM-1), inflammatory
enzymes (e.g., iNOS, COX-2), and apoptotic regulators
(e.g., Fas ligand, Fas, p53) [85].
Oxidized LDL may affect atherogenesis in part via the NF-
κB activation pathway. Oxidized LDL activates NF-κB as
well as C. pneumoniae [86]. Resveratrol, an antioxidant
polyphenol derived from plants, attenuates TNF-α-
induced inflammatory gene expression and monocyte
adhesion to human coronary arterial endothelial cells
(HCAECs) by inhibiting NF-κB activation, suggesting that
the anti-inflammatory actions of resveratrol are responsi-
ble for anti-atherogenic effects [78]. Oxidized LDL exerts
biphasic effects on NF-κB: 1) inflammatory effects by up-
regulating inflammatory gene expression via NF-κB acti-
vation at lower concentrations of oxidized LDL; and 2)
immunosuppressive effects by inhibiting NF-κB activa-
tion triggered by inflammatory agents such as lipopoly-
saccharide (LPS) at higher concentrations of oxidized LDL
[85]. HUVECs incubated with LPS which causes inflam-
matory gene expression via TLR4 activation, induce the
expressions of TLR4, LOX-1, ICAM-I, and E-selectin, and
increase monocyte adhesion to endothelium and NF-κB
activation levels, suggesting the atherogenic process is
mediated through TLR4/NF-kB pathways [87]. There are
two types of TLR4/NF-κB pathways identified: MyD88-
dependent and independent pathways. MyD88 is a com-
mon downstream adaptor molecule for most TLRs, and
recruits other molecules required to activate NF-κB. Satu-
rated fatty acids trigger TLR4 and downstream NF-κB acti-
vations, resulting in inflammatory gene expression (i.e.
COX2 or iNOS). In contrast, unsaturated fatty acids
inhibit TLR4/NF-κB activation. This inhibition may be
due to the alteration of fatty acid components in mem-
brane lipid rafts, which may lead to the disruption of the
recruitment of the downstream signaling components
[61].
PPARs
PPARs (PPARα, PPARβ, and PPARγ), a group of nuclear
receptors, belong to the steroid hormone receptor super-
family [88]. PPARs heterodimerize with the 9-cis retinoic
acid receptor (RXR) and bind to peroxisome proliferator
response elements (PPREs: 5'-AGGTCAnAGGTCA-3')
which are located in enhancer sites of target genes (Figure
4). PPARα and PPARγ are expressed in vascular endothe-
lial cells and smooth muscle cells as well as adipose tis-
sues [79,89]. PPARα and PPARγ play a role in
Role of PPARγ Figure 4
Role of PPARγ. Peroxisome proliferator response element (PPRE), retinoic X receptor (RXR), retinoic acid (RA), ligands (L).Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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inflammation, adipogenesis, and insulin sensitization.
Thiazolidinediones (TZDs), a group of synthetic PPARγ
ligands, have shown beneficial effects as atheroprotective
drugs. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), an
prostanoid, is a natural ligand and an activator for PPARγ.
15-LOX products, 9- and 13-hydroxy-octadecadienoic
acids (HODEs), are also PPARγ activators [89]. Therefore,
these eicosanoids, 15d-PGJ2 and HODEs, support the
implication of PPARγ in inflammation.
PPARγ activation may be involved in oxidized LDL-
induced inflammatory gene expression and macrophage
lipid metabolism [45,90,91]. Although CD36 is up-regu-
lated by oxidized LDL via PPARγ activation, PPARγ activa-
tion suppresses oxidized LDL-induced inflammatory
effects by inhibiting inflammatory gene expression. Kun-
sch and Medforld [82] suggest that PPARγ participates in
a positive feedback loop and that alternative or down-
stream pathways may trigger PPARγ activation resulting in
anti-inflammatory effects. For example, 15d-PGJ2 is
known to be an endogenous PPARγ activator. 15d-PGJ2
may be a possible anti-inflammatory mediator, though
the physiological levels of 15d-PGJ2 may be insufficient
to modulate PPARγ activation [92]. PPAR activators are
negative regulators of macrophage activation and antago-
nize the activities of the transcription factors, AP-1, STAT,
and NF-κB, involved in inflammatory gene expression
[93,94].
Lipoprotein lipase (LPL), a lipolytic enzyme, may play an
important role in regulating early atherogenesis. LPL nei-
ther acts on nor binds to oxidized LDL. LDL(-) is a form
of native LDL containing intermediately modified sub-
fractions with higher electronegative charge and is taken
up by LDL receptors. Lipid peroxidation is greater in
LDL(-) than in native LDL; LDL(-) exhibits inflammatory
effects. Ziouzenkova et al. [95] demonstrated that LPL-
treated LDL(-) reduced inflammatory gene expression in
human ECs by suppressing NF-κB and AP-1 activations
and by increasing the expression of IκB, a target gene for
PPARα, via PPARα activation. In contrast, LDL(-) alone
increased the inflammatory responses. 9- and 13-HODEs,
both known as PPARγ activators, are released during the
hydrolysis of both native LDL and LDL(-), resulting in
PPARα activation and anti-inflammatory effects.
Expression of antioxidant enzymes, Cu/Zn SOD and cata-
lase, may be modulated through both PPARγ and NF-κB
activations. Possible multiple binding sites for PPARγ and
NF-κB have been identified: 1) within the promoter
region of SOD1, and 2) one binding site for NF-κB within
the promoter region of catalase. NF-κB activation is asso-
ciated with the induction of proinflammatory gene
expression. Although Cu/Zn SOD is an antioxidant
enzyme, it is induced to convert superoxide to hydrogen
peroxide that is still microbicidal; it also serves as a host
defense with NADPH oxidase in phagocytes. Further-
more, the treatments of possible PPARγ activators increase
both PPARγ and NF-κB DNA binding activities, indicating
that these two redox-sensitive transcription factors coordi-
nate and propagate feedback loops between each other.
Interactions between genes and diet: Risk 
factors
Single-nucleotide polymorphisms (SNPs) are a genetic
variation of differences in a single nucleotide between
individuals. The gene-diet interaction between common
SNPs located in candidate genes and dietary factors
related to lipid metabolism has been recently reported
[96]. These candidate genes include: APOA1  (75G→A)
encoding apolipoprotein A-I, an apolipoprotein of HDL,
and PPARA (Leu162Val) encoding PPARα. Ordovas et al.
and Tai et al. suggest specific interactions between these
polymorphisms and lipid profiles. HDL-cholesterol con-
centrations increased significantly with increasing PUFA
intake in women with the A allele (G/A and A/A) in
APOA1, while HDL-cholesterol concentrations decreased
as PUFA intake increased in women with the homologous
G allele (G/G) in APOA1 [97]. The Leu162Val polymor-
phism in PPARA is associated with increased plasma con-
centrations of total cholesterol, LDL cholesterol, and
apolipoprotein B [98]. Thus, these interactions influence
CVD risk in different directions through effects on two dif-
ferent CVD risk factors: HDL cholesterol through the pol-
ymorphism in APOA1and triacylglycerol through the
polymorphism in PPARA. The effects of Pro12Ala poly-
morphism in PPARG2 on type 2 diabetes and obesity are
also reported. The 12Ala allele (Ala/Ala) in PPARG2 con-
fers a reduced risk for type 2 diabetes and decreased obes-
ity-associated insulin resistance in the French Caucasian
population [99]. Furthermore, the associations of poly-
morphisms in genes involved in antioxidant defense sys-
tems, with CVD and other diseases, have been proposed.
A human sodium-dependent vitamin C transporter,
SVCT1, is encoded by SLC23A1, and mediates intestinal
absorption and renal absorption of L-ascorbic acid [100].
SLC23A1  appears to have population-specific variants,
and populations with discrete genetic variants might
require different recommended values of vitamin C intake
to maintain health and/or to prevent disease [101]. An
antioxidant enzyme, SOD2 (Mn-SOD), is constitutively
expressed in most cells. The SOD2 polymorphism, 16Val
homozygous, may be a predisposing factor for lung can-
cer, cardiomyopathy, diabetic complications, hyperten-
sion, and CVD [102-105] and may influence longevity
[106]. GPX1 encodes Gpx1, and may be a target gene for
exploring roles of its variants in the etiology of various
human diseases [107]. Genetic variations may also affect
inflammatory responses. TLR4 is a pattern recognition
innate immunity receptor that binds LPS found in gram-Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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negative bacterial walls and possibly oxidized LDL [15].
The Asp299Gly TLR4 polymorphism may decrease the
risk of atherosclerosis by reducing TLR4 receptor signaling
and subsequent inflammatory response [61,108].
Thus, genetic variations are widely distributed in various
components involved in atherogenesis. The total genetic
variations between individuals may differently influence
the risk for and the etiology of atherosclerosis and CVD. It
may be possible to provide individuals with dietary/ther-
apeutic guidance tailored to their genotypes, given ade-
quate information on the interaction between specific
genetic polymorphisms and diet [109]. In other words,
genetic variations might predict the significant differences
in disease etiology between different species, thus suggest-
ing the limitation of animal studies. Hence, nutrigenetics
and nutrigenomics would be new powerful tools for
investigating the relations between diseases and genes at
individual/intra-species levels.
Experimental studies of CLA isomers
Animal studies
Rabbits
The possibility that the anti-atherogenic properties of CLA
isomers may influence atherosclerotic lesions and blood
lipid levels has been tested in animal models.
Rabbit studies suggest protective and/or therapeutic
effects of CLA isomer treatments. Rabbits fed an athero-
genic diet and supplemented with CLA isomer mixture
(cis-9, trans-11 CLA isomer: trans-10, cis-12 CLA isomer =
1:1; 0.5 g CLA diet/day/rabbit) had significantly less aortic
fatty lesions and lower levels of plasma triglycerides and
LDL-cholesterol, compared to control animals [110]. A
rabbit study by Kritchevsky et al. [46] also reported
reduced atheromatous lesions to the same extent in all
CLA-fed groups (90 days): 1% (final dietary concentra-
tion) each of the cis-9, trans-11 CLA isomer, the trans-10,
cis-12 CLA isomer, and the two isomer mixture, compared
to control group.
A dose-dependent effect of CLA isomer mixture (cis-9,
trans-11 CLA isomer: trans-10, cis-12 CLA isome r = 1:1)
on atherosclerotic regression was demonstrated in two
rabbit studies [47,111]. New Zealand white rabbits fed a
0.1% (final dietary concentration) CLA isomer mixture
diet after receiving an atherogenic diet, showed an inhibi-
tion of atherogenesis, while rabbits fed a 1% CLA mixture
diet exhibited a 30% regression of established atheroscle-
rosis [47]. Dose-dependent regression of established
atherosclerosis was seen in rabbits fed CLA isomer mix-
tures ranging between 1 and 10 g/kg body weight. How-
ever, both serum cholesterol and triglyceride levels were
higher in CLA fed groups than in control group, despite a
dose-dependent reduction of lipid levels within the range
of CLA isomer mixtures [111].
Mice
Mouse model studies suggest the anti-atherogenic effects
of CLA isomers, and some of those studies indicate that
the effects of CLA are tissue- (i.e, hepatoxicity described
later in this section), isomer-, and dose-specific.
Atherosclerotic prone strain C57BL/6 mice fed an athero-
genic diet containing 2.5 or 5 g/kg body weight CLA iso-
mer mixture (cis-9, trans-11 CLA isomer: trans-10, cis-12
CLA isomer = 1:1) for 15 weeks developed higher serum
HDL-cholesterol (total cholesterol ratio and lower serum
triacylglycerol concentration) than controls. However,
despite causing a serum lipoprotein profile considered to
be less atherogenic, addition of CLA isomer mixture to the
atherogenic diet increased the development of aortic fatty
streaks. Mice consuming a diet of 2.5 g CLA isomer mix-
ture/kg body weight, but not 5.0 g CLA isomer mixture/kg
body weight, developed a significantly greater area of fatty
streaks than the controls [112], suggesting dose-specifi-
city. A study by Arbones-Mainar et al. [113] showed iso-
mer-specific effects on the development of
atherosclerosis. The trans-10, cis-12 CLA isomer diet (1%
final dietary concentration for 12 weeks fed to apolipo-
protein E knockout mice) increased the values of blood
lipid, an inflammatory marker (8-iso prostaglandin E),
atherosclerotic plaque, and macrophage content and acti-
vation. However, the cis-9, trans-11 CLA isomer diet (1%)
inhibited atherogenic development. Moreover, de Roos et
al. [114] documented that CLA isomers differentially
affect plasma lipid levels as well as the markers of insulin
resistance and inflammation in apolipoprotein E knock-
out mice. The cis-9, trans-11 CLA isomer lowered these val-
ues suggesting beneficial properties, whereas the trans-10,
cis-12 CLA isomer increased the values indicating detri-
mental properties. In Nestel et al's study [115] using insu-
lin deficient apoE deficient mouse models, 0.9% (final
dietary concentration) cis-9,  trans-11 CLA isomer diet
failed to reduce the severity of aortic atherosclerosis,
though plasma triglyceride levels decreased, and HDL
cholesterol levels increased.
Hamsters
Like mouse models, hamster models have shown protec-
tive effects, some of which are isomer-specific. Hamsters
fed a CLA isomer mixture diet (cis-9, trans-11 CLA isomer:
trans-10, cis-12 CLA isomer = 1:1, final dietary concentra-
tions 0.06, 0.11, and 1.1%) showed significantly reduced
plasma levels in total cholesterol, non-high-density lipo-
protein cholesterol, and triglycerides [116]. In Wilson et
al's study [117] using hamster models, animals on the
hypercholesterolemic diet (HCD) supplemented 1%
(final dietary concentration) CLA isomer mixture diet (cis-Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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9, trans-11 CLA isomer: trans-10, cis-12 CLA isomer = 1:1)
showed 47% fewer aortic fatty streaks and lower plasma
cholesterol levels than control. In addition, the CLA iso-
mer mixture diet reduced the development of early aortic
atherosclerosis to a greater degree than linoleic acid, pos-
sibly through changes in LDL oxidation susceptibility in
hypercholesterolemic hamsters. Both the cis-9,  trans-11
and trans-10, cis-12 CLA isomer (1% diet of each isomer)
fed groups of hamsters had non-significantly decreased
fatty streak lesions. However, neither diet affected plasma
cholesterol levels [118]. Wilson et al. [119] later reported
the adverse effects of the trans-10, cis-12 CLA isomer, but
not the cis-9, trans-11 CLA isomer, suggesting an isomer-
dependent effect of CLA on atherogenesis in hypercholes-
terolemic hamster models. In the Wilson et al's study,
hamsters were divided into four groups and were fed for
up to 12 weeks: 1) an HCD, 2) an HCD with 0.5% (of
diet) cis-9, trans-11 CLA isomer, 3) an HCD with 0.5% (of
diet) trans-10, cis-12 CLA isomer, or 4) an HCD with lino-
leic acid (LA). Both CLA fed groups had lower blood cho-
lesterol levels. However, the trans-10, cis-12 CLA isomer
fed group had higher plasma triglyceride and glucose lev-
els compared with the control at 12-weeks of treatment,
while the plasma triglyceride and glucose levels of the cis-
9, trans-11 CLA isomer fed group were reduced. Wilson et
al. concluded that the trans-10, cis-12 CLA isomer may be
detrimental if fed separately from the cis-9, trans-11 CLA
isomer. In contrast, Navarro et al. demonstrated favorable
effects of the trans-10, cis-12 CLA isomer on lipid metabo-
lism in the blood and the liver of hamsters fed an athero-
genic diet for 6 weeks and no effects of the cis-9, trans-11
CLA isomer on the same lipid metabolisms [120]. Studies
by Valeille et al. [121,122] exhibited the anti-atherogenic
and anti-inflammatory effects of the cis-9, trans-11 CLA
isomer in hyperlipidemic hamsters.
Inter-/intra-species, tissue-, isomer-specificities
At dietary levels of 0.1–1%, the CLA isomer mixture
caused substantial regression of established atherosclero-
sis in earlier rabbit models [46,47,111]. This was a unique
and important finding, because once established, aortic
lesions in rabbits will regress only under unusual circum-
stances. Regression of pre-established lesions has never
been achieved by dietary means or by simple pharmaco-
logic intervention in vivo. However, the use of rabbit mod-
els for atherosclerotic studies may not be suitable. Unlike
humans, the majority of rabbit blood cholesterol is β-
VLDL. Therefore, the aortic lesions caused by feeding
atherogenic diets to rabbits may not be comparable to
those seen in humans. In contrast, LDLR- or apo-E-defi-
cient mouse models mimic human atherosclerosis [123].
Thus, the effects of dietary CLA isomer supplementation
have not been consistent between these different animal
models. Even between rats and mice, a different species
response to CLA isomers has been indicated. Any
response of peroxisome proliferattion to CLA isomers
may be greater in mice than in rats [124]. CLA isomers are
known to be PPAR activators [6]. Differences in CLA-
mediated hepatic gene induction between mice and rats
have also been found [125]. Hepatic fat accumulation
caused by the trans-10,  cis-12 CLA isomer has been
reported mainly in mice, and hepatic fat accumulation is
associated with the loss of adipose tissue induced by the
trans-10,  cis-12 CLA isomer [126]. Adipose tissues are
important endocrine organs that produce inflammatory
mediators such as TNFα and IL-6 and -8, and adipocy-
tokines (adiponectin and leptin). Adipocytokines are key
regulators of insulin resistance. Adiponectin and leptin
affect immune and inflammatory functions [127]. The
dramatic decrease in adiponectin concentrations is impor-
tant to the development of hepatic steatosis and insulin
resistance induced by CLA. Removing CLA from the diet
rescued leptin and adiponectin levels and attenuated insu-
lin resistance induced by dietary CLA in mice. However, if
a PPARγ activator, rosiglitazone, was added to CLA-TG
diet (38.5% trans-10, cis-12 CLA isomer), the reduction in
adipose mass and serum leptin and adiponectin levels was
reversed [128].
An opposite response to that found in mice, CLA mixture
diet (39.2% the cis-9, trans-11 and 38.5% trans-10, cis-12
CLA isomers) reduces hepatic steatosis and plasma lipids
in rats [129,130]. Beyond rodent models, the genetic dif-
ferences between mice and humans should be considered.
For example, mice contain more copies of cytochrome
P450 than do humans [131]. Cytochrome P450 is
involved in microsomal ω-oxidation of fatty acids, eicosa-
noid synthesis, and detoxification of xenobiotics. The
trans-10,  cis-12 CLA isomer significantly reduces cyto-
chrome P450 gene expression in mouse livers, and the
reduction may contribute to CLA-induced fatty livers as
well as the induction of enzymes associated with fatty acid
synthesis [126]. Thus, not only are there differences in
CLA-mediated cytochrome P450 gene expression, there
are additional differences in fatty acid metabolism and
eicosanoid formation, between humans and mice. As
described in Section 6, single nucleotide polymorphisms
(SNPs) among human individuals, such as SNPs in
APOA1, PPARA, PPARG, SOD2, Gpx1, and TLR4, may also
cause differences in lipid metabolism and the risk for
atherosclerosis. In addition, the age of animals fed CLA
and examined may be another consideration. Many
atherosclerotic studies used adolescent individuals for
their animal models. Adolescent animals are still growing;
their body composition is still changing. The gene expres-
sion profile and sensitivity to and metabolism of chemi-
cals in a developmental stage differ from those in adults.
Such differences may make the extrapolation to humans
from animals and explanations of study results more dif-
ficult. Thus, there are several factors to be consideredNutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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when investigating the effects of CLA isomers as therapeu-
tic or chemopreventive agents for atherosclerosis: dose-
dependency and isomer-specificity, as well as inter- and
intra-species differences. Therefore, genetic and genomic
research using human subjects and/or human cells are
urgently needed to determine the effects of each isomer.
Human Studies
CLA is being sold as a panacea with several alleged bene-
fits including altering body composition, i.e., to reducing
obesity and building lean body mass [132]. Safety of long-
term (≥ 12 months) CLA supplementation was examined
in several clinical trials. A randomized, double-blind
study was conducted, in which obese individuals were
given 6 g/day of either CLA isomer mixture (cis-9, trans-11:
trans-10, cis-12 = 50:50) or placebo (high oleic sunflower
oil) for 12 months. Although body composition did not
differ between the CLA-supplemented group (n = 27) or
the placebo group (n = 23), lower levels of adverse effects
(alterations in the liver function, glucose and insulin lev-
els, insulin resistance, and white blood cell counts) were
observed in the CLA-supplemented group than in the con-
trol group. The investigators concluded that CLA isomer
mixture as Clarinol™ is safe for use in obese humans for
up to one year at the recommended dosage [133]. Another
long-term (one year) CLA isomer mixture supplementa-
tion study was performed in a double-blind fashion
[134]. Healthy overweight humans (n = 180) were ran-
domly divided into three groups: 1) CLA free fatty acid
(cis-9,trans-11: trans-10, cis-12 = 50:50; 3.6 g CLA isomers/
day as FFA forms), 2) CLA-triacylglycerol group (cis-9,
trans-11: trans-10, cis-12 = 50:50; 3.4 g CLA isomers/day as
TAG forms), and 3) placebo (olive oil). The CLA isomer
mixture supplementation decreased body fat mass in
healthy overweight adult humans. However, there were
significant increases in: LDL levels in the CLA-FFA group,
HDL levels in the CLA-TAG group, and lipoprotein levels
in both CLA groups. Adverse effects, mostly gastrointesti-
nal, were reported by 11.4% of the subjects, and likely
resulted from the daily ingestion of oil or of the gelatin
capsule alone. Overall, the adverse effects did not differ
significantly between the CLA groups and the placebo
group, indicating that CLA isomer mixture was tolerated
as well as olive oil as the control. One hundred twenty five
of 180 subjects who finished this study, continuously par-
ticipated in the CLA isomer mixture supplementation
study for an additional year, thus, total 2 years [135]. Two-
year-CLA isomer mixture supplementation groups signifi-
cantly reduced body weight, BMI, body fat mass, energy
intake and serum leptin levels, compared with the base-
lines at month 0. However, serum lipoprotein and aspar-
tate amino transferase levels, and whole blood leukocyte
and thrombocyte counts were significantly increased in
the CLA groups. Gaullier et al. concluded that CLA isomer
mixture supplementation for 24 months in healthy, over-
weight adults was well-tolerated, and that CLA isomer
mixture may be beneficial as a weight loss supplement.
Another one-year CLA isomer mixture supplementation
study [136] was conducted in a randomized, double-
blind, placebo-controlled fashion. No significant differ-
ences in body weight or body fat regain were observed
between the CLA group (cis-9, trans-11: trans-10, cis-12 =
50:50; 3.4 g/day as TAG forms; n = 40) and placebo (4.5
g olive oil; n = 43). No significant differences in adverse
effects or indexes of insulin resistance were observed
between the groups. However, a significant increase in the
number of leukocytes was observed in the CLA group.
Although the investigators did not obtain a perfect group
match for body weight at randomization, they concluded
that the CLA isomer mixture supplementation for one
year has no preventative effect on body weight and body
fat regain after the weight loss induced by a low calorie
diet for eight weeks in obese subjects.
Many studies have investigated the effects of short-term
(mostly 12 weeks or 8 weeks) CLA supplementation. In a
six-month double-blind CLA isomer mixture supplemen-
tation study [137], 118 healthy overweight and obese
adult humans were randomized into two groups supple-
mented with either 3.4 g/day CLA isomer mixture (cis-9,
trans-11: trans-10, cis-12 = 50:50) or placebo. CLA signifi-
cantly decreased body fat mass, in particular in legs of
both males and females and in females with BMI >30 kg/
m2, at either month 3 or 6, compared with placebo. Lean
body mass increased in the CLA supplemented group. The
safety parameters including blood lipids, inflammatory
and diabetogenic markers remained within the normal
range, and adverse events did not differ between the
groups in the study. It was concluded that the CLA isomer
mixture supplementation in healthy, overweight, and
obese subjects decreases body fat mass in specific regions
and was well tolerated. The dose-dependent effects of CLA
were reported in a CLA isomer mixture supplementation
study of 12 weeks [138]. Forty eight obese subjects were
divided into three groups: 1) 3.2 g/day CLA (cis-9, trans-
11: trans-10, cis-12 = 50:50), 2) 6.4 g/day CLA, and 3) pla-
cebo (8 g safflower oil). CLA isomer mixture supplemen-
tation at the higher dose increased inflammatory markers,
IL-6 and C-reactive protein (CRP), however, remained
within normal ranges. A significant increase in lean body
mass was also found in the same treatment group. No
severe adverse effects were reported. The authors con-
cluded that the CLA isomer mixture intervention was well-
tolerated. Beneficial effects on immune functions have
been reported in a double-blind, randomized CLA isomer
mixture supplementation study [139]. Twenty-eight
healthy adults received either high oleic sunflower oil
(placebo) or 3.0 g/day CLA (cis-9, trans-11: trans-10, cis-12
= 50:50; triglyceride form) for 12 weeks. The CLA group
showed significantly reduced levels of the proinflamma-Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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tory cytokines, TNF-α and IL-β, and increased levels of the
anti-inflammatory cytokine, IL-10. Immunoglobulin lev-
els were also altered: CLA isomer mixture decreased Ig E
levels, and increased both Ig M and Ig A levels. Another
CLA isomer mixture supplementation study (2.2 g/day;
cis-9, trans-11: trans-10, cis-12 = 50:50; 8 weeks) investi-
gated the effects of CLA isomer mixture on inflammation
in a double-blind, randomized, placebo-controlled
model using healthy middle-aged males [140]. The CLA
isomer mixture supplementation significantly reduced
concanavalin A-stimulated peripheral blood mononu-
clear cell IL-2 secretion, suggesting anti-inflammatory and
anti-atherogenic effects of CLA isomer mixture. Other
inflammatory markers, IL-6, CRP, and fibrinogen, were
not affected in this study. Moloney et al. [141] demon-
strated that the CLA isomer mixture supplementation (3.0
g/day; cis-9, trans-11: trans-10, cis-12 = 50:50; 8 weeks)
increased total HDL cholesterol concentrations and
decreased the ratio of LDL cholesterol to HDL cholesterol
without changes in inflammatory markers of CVD in sub-
jects with type 2 diabetes. However, this CLA isomer mix-
ture intervention did not show positive effects on insulin
and glucose concentrations among the diabetic patients.
In a Swedish study, 53 healthy humans were randomly
assigned to CLA isomer mixture supplementation (4.2 g/
day; cis-9, trans-11: trans-10, cis-12 = 50:50; 12 weeks) in a
double-blind fashion. Supplementation with a CLA iso-
mer mixture reduced the proportion of body fat and
affected fatty acid metabolism. However, no effects were
found for CLA isomer mixture on body weight, serum lip-
ids, glucose metabolism or plasminogen activator inhibi-
tor 1 [142]. In Noone et al.'s double-blind placebo-
controlled study [143], the CLA isomer mixture treatment
(3 g/day; cis-9, trans-11:trans-10, cis-12-CLA = 50:50; 8
weeks) showed reduced plasma triacylglycerol levels in
normolipaemic human subjects.
A study using 49 healthy male subjects showed the iso-
mer-/dose-dependent (0.59, 1.19, 2.38 g/day of the cis-9,
trans-11 CLA isomer; 0.63, 1.26, 2.52 g/day of the trans-
10, cis-12 CLA isomer; 8 weeks) opposite effects of CLA on
plasma total cholesterol and LDL-cholesterol levels:
hypolipidemic properties of the cis-9, trans-11 CLA isomer
and hyperlipidemic properties of the trans-10, cis-12 CLA
isomer. However, neither CLA isomer supplementation
affected insulin resistance [144]. Using the same healthy
male subjects and the same supplementation design, Tri-
con et al. investigated the effects of two CLA isomers on
immune cell functions [145]. The results showed a dose-
dependent reduction in the mitogen-induced activation
of T lymphocytes and a negative relationship between the
mitogen-induced T lymphocyte activation and the con-
tents of each CLA isomer in mononuclear cells, suggesting
beneficial effects in inflammatory diseases such as athero-
sclerosis.
Additional adverse effects of CLA supplementation, in
particular trans-10, cis-12 CLA, were reported. Riserus et al.
demonstrated that the purified trans-10, cis-12 CLA iso-
mer supplementation (3.4 g/day, 3 months), but not CLA
mixture supplementation (3.4 g/day; cis-9, trans-11: trans-
10, cis-12 = 50:50; FFA form, 3 months), increased oxida-
tive stress, CRP, and proinsulin levels, and decreased insu-
lin sensitivity in non-diabetic abdominally obese males
[146] and in males with metabolic syndrome [147] in two
double-blind, randomized, placebo- (3.4 g/day, olive oil)
controlled studies. Like the study by Tricon et al. [144],
Riserus et al.'s two studies also suggest the isomer-depend-
ent detrimental effects of CLA. Another unfavorable effect
of the trans-10, cis-12 CLA isomer was also reported in a
human study examining non-enzymatic and enzymatic
lipid peroxidation (8-iso-PGF2α  and 15-keto-dihydro-
PGF2α, respectively) in human plasma and urine. Sixty
healthy subjects were divided into six groups: three CLA
isomer mixture groups, (3.5 g/day, cis-9, trans-11: trans-
10, cis-12 = 50:50, 4 weeks) and three trans-10, cis-12 CLA
isomer groups (4.0 g of the trans-10, cis-12 CLA isomer/
day, 4 weeks): 1) the CLA supplement alone, 2) with vita-
min E (D-α-tocopherol acetate), and 3) with COX-2
inhibitor (refecoxib). Although both CLA isomer mixture
and the trans-10,  cis-12 CLA isomer supplementations
increased the eicosanoid levels in the urine, the trans-10,
cis-12 CLA isomer supplementation with the COX-2
inhibitor suppressed the increase in urinary 15-keto-dihy-
dro-PGF2α levels. This result suggests that increased lipid
peroxidation in eicosanoid synthesis may be due to
induced COX-2 expression by the CLA supplementations,
in particular the trans-10, cis-12 CLA isomer [148]. Taylor
et al. [149] documented that CLA isomer mixture supple-
mentation (4.5 g/day; cis-9,  trans-11:  trans-10,  cis-12 =
50:50; 12 weeks) impaired endothelial function and
increased markers of oxidative stress in 40 healthy white
males, suggesting caution in the use of CLA isomers as an
aid for weight loss.
Overall, the effects of CLA isomers (or mixture) on ather-
ogenic and/or inflammatory parameters in humans have
not been definitive. Although a meta-analysis of 18 CLA
human studies (including three single isomer studies)
suggests the beneficial use of CLA isomers only as a body
fat reducing supplement [150], the therapeutic potentials
of CLA isomers in inflammatory diseases including
atherosclerosis remain to be determined. Differences in
purity and content of CLA isomers may cause these con-
flicting results. Impurities might induce undesirable side
effects [151]. The variety of CLA isomer content in supple-
ments and/or the differences in CLA dose might cause
inconsistent results due to the dose- and/or isomer-
dependent effects of CLA suggested by some other studies
[138,144,146,147]. Human subjects were not limited in
diet (therefore, dietary fat intake, excluding supplementalNutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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fat intake, is of concern) and/or physical activities in some
study designs. In addition, CLA isomer (or mixture) sup-
plementations contained other fatty acids, including
PUFAs and saturated fatty acids, at up to 20% in some
study designs. The details of supplemental contents, other
than CLA isomers, are not even provided in some other
studies. Since CLA isomers are incorporated into mem-
brane phospholipids, they may compete in enlongation
and desaturation steps with other PUFAs that are precur-
sors of arachidonic acid (AA, 20:3, ω-6). The competition
in the incorporation may alter eicosanoid biosynthesis
[152], therefore, subsequent immune and inflammatory
processes. An experiment by Brown et al. [153] found that
the presence of linoleic acid (LA) may affect the possible
benefits of CLA isomers. LA, one of the PUFAs present in
Western diets and the human body is a possible antago-
nist to CLA isomers. The plentiful LA may exclude CLA
isomers from incorporation into phospholipids and drive
it into storage as a component of neutral lipid [52]. LA
also inhibits EPA incorporation in membrane phospholi-
pids from fish-oil supplements [54]. Like CLA isomers,
dietary EPA and DHA partially replace AA derived from LA
in the cell membrane. These ω-3 fatty acids are associated
with decreased risk for CVD, and reduce the formation of
pro-inflammatory eicosanoids [53]. The replacement of
AA by ω-3 fatty acids may cause the alteration of fatty acid
composition in membrane lipid bilayers influencing sign-
aling pathways and subsequent immune and inflamma-
tory processes. The anti-inflammatory effects of CLA
isomers observed in a limited number of studies may be
attributed to the replacement of AA generated by LA. In
addition, saturated fatty acids have been reported to pro-
voke inflammation by inducing pro-inflammatory gene
expression through innate immune receptor (TLRs) acti-
vation [61]. Thus, the coexistence of other fatty acids
might potentially affect the results of any human studies
with CLA isomers. Moreover, there may be divergent
effects of CLA isomers in obese or diabetic subjects com-
pared to the normal-weight or healthy subjects as well as
differences determined by gender and/or genetics, i.e.,
SNPs in related genes. Further studies are needed to inves-
tigate the effectiveness and safety of CLA supplementation
and to elucidate these confounding factors.
CLA mediated gene expression
Adiposity plays an important role in fatty acid mobilization,
fat storage, and formation of pro-and anti-inflammatory
cytokines and chemokines [128]. As mentioned above,
atherosclerosis is viewed as a chronic inflammatory dis-
ease affecting lipid profiles. CLA isomers have been
shown to influence lipid metabolism associated with
inflammation and atherogenesis in in vitro studies. One
possible mechanism by which CLA isomers could modu-
late atherogenesis is regulating the production of lipopro-
teins in the liver. Sterol element binding proteins (SREBP)
are a group of membrane-bound transcription factors that
bind to their specific DNA binding sites (SRE-1) to acti-
vate the expression of target genes that encode enzymes
necessary for lipid synthesis, including the LDL receptor
(LDLR) gene in sterol-depleted cells [154]. A study by
Ringseis et al. [155] reported that the trans-10, cis-12 CLA
isomer, not the cis-9, trans-11 CLA isomer, induced LDLR
gene expression via SREBP-2 in human hepatoma cells
(HepG2). They concluded that the enhanced uptake of
VLDL and LDL cholesterols by hepatic LDLR may account
for the decreased plasma cholesterol levels in response to
CLA isomer (or mixture) supplementations in a limited
number of human and animal studies. An alternative
pathway for CLA-mediated LDLR expression is also sug-
gested. Yu-Poth et al. [156] demonstrated that a CLA iso-
mer mixture (50:50, 400 μmol/L final concentration) up-
regulated LDL receptor (LDLR) mRNA and protein expres-
sion at three- to five-fold in HepG2 cells. The results of the
study suggest the upregulation of the LDLR gene by CLA
through a mechanism that is independent of SREBP-1 and
acyl CoA: cholesterol acyltransferase (ACAT).
Monocyte-endothalial interaction is a key step of athero-
genesis. However, CLA isomers showed no effects on
TNFα-induced adhesion molecule expression, monocyte
adhesion, and chemokine release or on the molecular
mechanisms regulating these processes in human aortic
endothelial cells [21]. This suggests that the anti-athero-
genic effects of CLA isomers may not be associated with
the reduction of monocyte-endothelial interactions.
Several studies have investigated the implication of CLA
isomers in eicosanoid synthesis and the role of CLA iso-
mers in inflammation and atherogenesis. Dietary CLA
may suppress the biosynthetic pathway of AA. CLA may
suppress eicosanoid formation via direct action on COX
and LOX, i.e., by inhibiting the expression or the activities
of these enzymes [5,6]. Constitutive COX-1 and inducible
COX-2 catalyze the conversion of free PUFAs to prosta-
noids, while LOX generates the leukotrienes. The trans-10,
cis-12 CLA isomer suppresses COX-2 expression and PGE2
release in rat macrophages either by inhibiting NF-κB acti-
vation in vivo and in vitro or by inhibiting the MAPK/ERK/
JNK pathway. The trans-10, cis-12 CLA isomer inhibits the
NF-κB p50 and p65 subunits binding to DNA [83]. The
50:50 mixture of CLA isomers inhibits the expression of
both COX-2 and inducible nitric oxide synthase (iNOS)
in LPS activated murine macrophages, resulting in
decreases in prostaglandin E2 and NO synthesis [157]. The
effects of CLA on prostanoid formation can be either
inhibitory or stimulatory, depending on isomer-specifi-
city, chemical forms of CLA isomers (i.e., free fatty acid or
esterified forms), or cellular states (i.e., resting or stimu-
lated states) in human endothelial cells and platelets
[158]. CLA isomers have also been reported to reduceNutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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prostaglandin E2 synthesis in certain cell types in both
humans and mice [159].
The beneficial effects of CLA isomers may be attributed to
their properties as PPARα/γ activators [5,48,155,160].
Structurally, CLA resembles 13-HODE, as well as 15-HETE
and 15d-PGJ2, which were all identified as natural activa-
tors of PPARγ [49]. Ringseis et al[160] demonstrated that
either the cis-9, trans-11 or trans-10, cis-12 CLA isomer (50
μmol/L) reduced AA proportions in human vascular
smooth muscle cells (SMCs), TNFα-induced NF-κB DNA
binding activity, mRNA levels of enzymes involved in
eicosanoid synthesis (e.g., COX-2), and production of
PGE2 and PGI2. These CLA isomer treatments increased
PPARγ DNA binding activity. Furthermore, a PPARγ
repressor suppressed the inhibitory actions on the eicosa-
noid formation and NF-κB DNA binding activity in the
SMCs. Synthetic PPAR activators exert their anti-inflam-
mtory actions, at least in part, by negatively regulating NF-
κB activation [157]. PPARγ and NF-κB may be involved in
regulating genes, whose products influence ROS genera-
tion that contributes to inflammation and atherogenesis,
and these transcription factors coordinate and propagate
feedback loops between each other. Thus, anti-inflamma-
tory and anti-atherogenic effects of CLA isomers may be
associated with these redox-sensitive transcription factors.
Although CLA isomers and ω-3 PUFAs have shown anti-
inflammatory effects, they differ in the nature of their
immunomodulatory properties. CLA isomers appear to
enhance immune function, while ω-3 PUFAs are immu-
nosuppressive [5]. Tian et al.'s study [51] using rats treated
with 300 mg/kg/day of clofibrate, a PPARα activator, for
up to 14 days, reported an increase in myocardial DHA
proportion and a decrease in the portion of AA that is a
precursor of pro-inflammatory eicosanoids (e.g., leukot-
riene B4 and prostaglandin E2). Tian et al. implicate
enhanced uptake of ω-3 PUFAs from blood circulation
and/or increased biosynthesis of ω-3 PUFAs in rats treated
with the PPARα activator, in those results. Similarly, Attar-
Bashi et al.'s human study [161] investigated the effects of
CLA isomers mixture [3.2 g/day, cis-9, trans-11: trans-10,
cis-12 = 50:50, plus 11 g of alpha-linoleic acid (ALA), 8
weeks] as PPARα activators on DHA (22:6, ω-3) and EPA
(20:5, ω-3) biosynthesis from ALA (18:3, ω-3) through
Δ5- and Δ6-desaturases, both of which are possible
PPARα target genes. The study demonstrated that ALA
(18:3, ω-3) plus CLA isomer mixture increased EPA and
decreased AA. However, the CLA isomer mixture supple-
mentation did not affect DHA biosynthesis in humans.
DHA synthesis from ALA needs additional peroxisomal
oxidation. Thus, CLA isomers may play a role in PPARα-
mediated gene expression and ω-3 PUFA-mediated anti-
inflammatory effects.
CLA isomers are readily metabolized in vivo via multiple
pathways, and enlongated and desaturated metabolites of
CLA have been detected in the liver and mammary tissue
of rats and adipose tissue and sera of humans [6]. Some
studies have suggested the involvement of CLA metabo-
lites in anti-atherogenic and ant-inflammatory processes
[5,160], though the Δ6-desaturase metabolites of CLA
may not be important for the alterations in gene expres-
sion induced by CLA [6].
Thus, multiple signaling pathways, such as PPARα,
PPARγ, NF-κB, and MAPK/ERK/JNK, may be involved in
the anti-inflammatory and anti-atherosclerotic effects of
CLA isomers.
Conclusion
Conjugated linoleic acid isomers are a group of zoochem-
icals that have a variety of physiological actions and
potential health benefits, e.g., modulation of inflamma-
tion, lean body mass, atherosclerosis, and cancer. Most of
the health effects of CLA isomers are based on reports with
limited power of extrapolation of experiments with ani-
mal models and in vitro/ex vivo systems. Multiple factors
in earlier animal studies might cause inaccurate extrapola-
tion of CLA isomer effects to humans. First, interspecies-
genetic differences may be a major consideration. Some of
the health effects of CLA isomers seen in animal models
might be species-specific, and might not be observable in
humans. For example, the suppressive effect on hyperten-
sion was seen in CLA fed rats [162-165], but not in
humans [166]. Second, animal studies used primarily
adolescent animals, while human studies used mostly
healthy, obese, or diabetic adults. Body composition, sen-
sitivity to and metabolism of chemicals, and gene expres-
sion profiles in developing adolescent animals may be
different from those seen in adult humans. This could
influence the outcome of examining the effects of CLA
isomers, in particular, on age-associated events, such as
adiposity and atherogenesis. Although atherosclerosis-
prone mice (i.e., C57BL/6) mimic humans, animal results
have been inconclusive and the efficacy of CLA isomers
maybe due to interspecies-gene differences. Third, animal
studies have usually been of short durations with high
dosages. This is of particular concern because extrapolated
CLA isomer dosages for possible human consumption
would require dose and duration adjustments for human
lifespan and levels at or less than threshold toxicity.
The effects of CLA isomers on body composition have
been studied extensively in animals and have recently
been repeated in human studies with conflicting findings.
In part, the results may be inconclusive because a majority
of the studies utilized CLA isomer mixture supplementa-
tion. Both dose- and isomer-dependent effects of CLA
have been suggested in both the animal and human stud-Nutrition & Metabolism 2008, 5:22 http://www.nutritionandmetabolism.com/content/5/1/22
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ies. Further research is needed to identify isomer-and/or
dose-related efficacy and toxicity. In addition, recent stud-
ies have identified SNPs in genes related to lipid metabo-
lism and antioxidant defense systems. It may be necessary
to investigate the effects of CLA isomers on CVD risk at
intra-species levels. Some recent animal studies have
reported a positive correlation with other disease preven-
tion and treatment, e.g., diabetes and inflammatory bowel
disease [48,49,128,129] leading researchers to further
evaluate the possible benefits of CLA isomer supplemen-
tation for humans.
Earlier research showed that the ability of CLA isomers to
act as anti-carcinogens and protectants against atheroscle-
rosis may be due to its role as an antioxidant. However, in
light of current research, the modulation of chronic dis-
eases by CLA isomers may involve the control of redox sta-
tus by regulating genes, whose products influence ROS
generation, through redox-sensitive transcription factors
including PPARγ and NF-κB. It is essential that investiga-
tion to develop an understanding about the molecular
action of CLA isomers be encouraged so that we may learn
how to use these compounds as adjuvants in chronic dis-
ease therapy.
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